2026-04-29T12:24:16Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/231362024-11-28T21:21:51Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16983
Repisalud author Montero, Maria M author Domene Ochoa, Sandra author López-Causapé, Carla author Luque, Sonia author Sorli, Luisa author Campillo, Nuria author Lopez Montesinos, Inmaculada author Padilla, Eduardo author Prim, Nuria author Angulo-Brunet, Ariadna author Grau, Santiago author Oliver, Antonio author Horcajada, Juan P 2024-09-18T06:41:59Z 2024-09-18T06:41:59Z 2021-09 Montero MM, Ochoa SD, Lopez-Causape C, Luque S, Sorli L, Campillo N, et al. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. Microbiol Spectr. 2021 Sep;9(1):e0058521. 10.1128/Spectrum.00585-21 2165-0497 Microbiology Spectrum https://hdl.handle.net/20.500.13003/19878 34319141 L2014554482 2-s2.0-85115900959 https://hdl.handle.net/20.500.12105/23136 703076500100 Ceftazidime-avibactam (CZA) has emerged as a promising solution to the lack of new antibiotics against Pseudomonas aeruginosa infections. Data from in vitro assays of CZA combinations, however, are scarce. The objective of our study was to perform a time-kill analysis of the effectiveness of CZA alone and in combination with other antibiotics against a collection of extensively drug-resistant (XDR) P. aeruginosa isolates. Twenty-one previously characterized representative XDR P. aeruginosa isolates were selected. Antibiotic susceptibility was tested by broth microdilution, and results were interpreted using CLSI criteria. The time-kill experiments were performed in duplicate for each isolate. Antibiotics were tested at clinically achievable free-drug concentrations. Different treatment options, including CZA alone and combined with amikacin, aztreonam, meropenem, and colistin, were evaluated to identify the most effective combinations. Seven isolates were resistant to CZA (MIC >= 16/4 mg/liter), including four metallo-beta-lactamase (MBL)-carrying isolates and two class A carbapenemases. Five of them were resistant or intermediate to aztreonam (MIC >= 16 mg/liter). Three isolates were resistant to amikacin (MIC >= 64 mg/liter) and one to colistin (MIC >= 4 mg/liter). CZA monotherapy had a bactericidal effect in 100% (14/14) of the CZA-susceptible isolates. Combination therapies achieved a greater overall reduction in bacterial load than monotherapy for the CZA-resistant isolates. CZA plus colistin was additive or synergistic in 100% (7/7) of the CZA-resistant isolates, while CZA plus amikacin and CZA plus aztreonam were additive or synergistic in 85%. CZA combined with colistin, amikacin, or aztreonam was more effective than monotherapy against XDR P. aeruginosa isolates. A CZA combination could be useful for treating XDR P. aeruginosa infections, including those caused by CZA-resistant isolates. IMPORTANCE The emergence of resistance to antibiotics is a serious public health problem worldwide and can be a cause of mortality. For this reason, antibiotic treatment is compromised, and we have few therapeutic options to treat infections. The main goal of our study is to search for new treatment options for infections caused by difficult-to-treat resistant germs. Pseudomonas aeruginosa is a Gram-negative bacterium distributed throughout the world with the ability to become resistant to most available antibiotics. Ceftazidime-avibactam (CZA) emerged as a promising solution to the lack of new antibiotics against infections caused by P. aeruginosa eng Ceftazidime-avibactam Colistin Aztreonam Amikacin Combination therapy Pseudomonas aeruginosa Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates research article